COLLEGIUM PHARMACEUTICAL, INC (COLL) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-15

Key Insights

Director Nancy Lurker sold 4,500 shares of COLL on 05/13/2026 at a weighted average price of $35.97, generating approximately $161,860 in proceeds, reducing her beneficial ownership to 18,017 shares.
The sale was executed across multiple transactions with prices ranging from $35.55 to $36.50, indicating an orderly liquidation rather than a panic sale at a narrow price band.
As a director selling a material portion of shares (approximately 20% reduction in her position), this insider transaction suggests either portfolio rebalancing or reduced conviction in near-term stock appreciation at current levels.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-13

Director Garen G. Bohlin executed a significant net sell transaction on 05/11/2026, selling 8,700 shares at a weighted average price of $37.18-$37.43 while simultaneously acquiring 8,700 shares at $16.49, representing a complex hedging or option exercise strategy rather than a pure directional bet.
The sale at $37.18+ represents a substantial premium over the acquisition price of $16.49, suggesting Bohlin may be realizing gains on stock option exercises or executing a pre-planned trading strategy to diversify holdings.
Bohlin's beneficial ownership decreased from 70,959 to 62,259 shares (net reduction of 8,700 shares or 12.3%), indicating insider selling pressure that could signal reduced confidence in near-term stock appreciation or portfolio rebalancing.
The stock option exercised (8,700 shares at $16.49 strike, expiring 06/09/2026) was fully vested and exercisable, suggesting this was a deliberate tactical execution rather than an automatic equity grant, with shares immediately sold at significantly higher prices.

Filed: 2026-04-03

The reporting person, David Dieter, who is the EVP & General Counsel of Collegium Pharmaceutical, Inc., disposed of 8,840 shares of the company's common stock to satisfy applicable withholding taxes upon the vesting of restricted stock units.
The transaction was executed on March 17, 2026, and Dieter still holds 68,231 shares of the company's common stock directly.
Insider transactions like this can provide insights into management's views on the company's stock and their confidence in its future performance.

Filed: 2026-03-20

The reporting person, Dieter David, sold 13,976 shares of the company's common stock on March 18, 2026, reducing their total beneficial ownership to 77,071 shares.
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.
The shares were sold at a weighted average price of $34.9241 per share, in multiple transactions ranging from $34.74 to $35.39 per share.

Filed: 2026-02-12

The reporting person, David Dieter, was granted 22,194 restricted stock units (RSUs) and 9,005 performance share units (PSUs) that vested, indicating potential alignment of executive compensation with company performance.
Dieter also sold 2,781 shares to cover tax withholding obligations, suggesting he is holding a significant portion of his equity awards.
The insider transactions suggest Dieter's continued commitment to Collegium Pharmaceutical and confidence in the company's future prospects.

Filed: 2026-02-12

Vikram Karnani, the President and CEO of Collegium Pharmaceutical, Inc., acquired a significant number of restricted stock units (79,264) and performance share units (32,531), indicating his commitment to the company's long-term growth.
Karnani also disposed of 11,296 shares to cover applicable withholding taxes, suggesting he is maintaining a substantial ownership stake in the company.
The vesting of the performance share units indicates the achievement of pre-determined performance criteria, which could signal positive business performance for Collegium Pharmaceutical.

Filed: 2026-02-12

Insider Thomas B. Smith, the EVP and Chief Medical Officer, has been granted 14,268 restricted stock units (RSUs) and 22,774 performance share units (PSUs) that have vested, indicating management's confidence in the company's performance.
Smith has also sold 5,897 and 11,538 shares to cover tax withholding obligations, suggesting he is not cashing out a significant portion of his holdings.
The company's share price of $46.75 at the time of the transactions suggests the stock is performing well, as the insider is not selling a large portion of his shares.

Filed: 2026-02-12

The reporting person, Colleen Tupper, was granted 26,421 restricted stock units (RSUs) and 32,734 performance share units (PSUs) on February 10, 2026, indicating management's confidence in the company's future.
Tupper also sold 11,861 shares to cover withholding taxes on the vesting of the PSUs and 26,679 shares to cover withholding taxes on the vesting of the RSUs, suggesting she is maintaining a significant ownership stake in the company.
The vesting schedule for the RSUs, with one-third vesting in the first year and the remaining two-thirds vesting over the next two years, provides incentives for Tupper to remain with the company and contribute to its long-term success.

Filed: 2026-02-12

The reporting person, Scott Dreyer, EVP & Chief Commercial Officer, has acquired a significant number of shares through restricted stock units (19,023) and performance share units (30,702), indicating confidence in the company's growth prospects.
Dreyer also sold a portion of his shares (9,977 and 21,615) to cover applicable withholding taxes, suggesting he may be managing his portfolio and liquidity needs.
The timing of the transactions, in February 2026, suggests these changes in beneficial ownership may be related to the company's compensation or incentive plans.

Other reports for COLLEGIUM PHARMACEUTICAL, INC

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.